FDA maintains clinical hold on DM199 stroke trial; company to conduct additional IV stability study

DiaMedica Therapeutics Inc.

FDA requires additional in-use in vitro stability study of IV administration of DM199 to resolve clinical hold on ReMEDy2 trial.
Company to request Type A meeting with FDA in coming weeks for guidance on lifting hold.
Cash and investments $36.1M as of Sep 30, 2022, down from $45.1M at Dec 31, 2021; runway into Q4 2024.
R&D expense Q3 2022 $1.6M (down from $2.3M Q3 2021); G&A $1.5M (up from $1.1M).
Net cash used in operating activities $8.7M for 9mo 2022, compared to $9.4M in 9mo 2021.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DiaMedica Therapeutics Inc. reported financial results for the three and nine months ended September 30, 2022.

Period: the three and nine months ended September 30, 2022
Result: reported results

Exact text from the filing

On November 9, 2022, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the three and nine months ended September 30, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

DiaMedica Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001437749-22-026608

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.